Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
2.
Int J Dermatol ; 57(7): 843-848, 2018 Jul.
Article in English | MEDLINE | ID: mdl-29704247

ABSTRACT

INTRODUCTION: Sjögren-Larsson syndrome (SLS) is a rare congenital disorder characterized by the triad of ichthyosis, spasticity, and mental retardation. Patients are usually referred to dermatology clinics during infancy. As paraplegia becomes the most debilitating symptom of the disease within a few years, ichthyosis, although a major burden for the patient, takes a back seat. Optimum treatment of ichthyosis in these children and the effect of treatment on different aspects such as severity of the ichthyosis, pruritus, or quality of life of the patients' and their caregivers is not well established. MATERIALS AND METHODS: Genetic background of eight patients from three families diagnosed clinically with SLS was determined with whole-exome and Sanger sequencing. Clinical phenotypes, laboratory findings, magnetic resonance imaging (MRI), and treatment of the ichthyosis with acitretin were assessed. RESULTS: All patients had the classical triad of Sjögren-Larsson syndrome. Genetic analysis revealed that one patient had a novel c.799-1 (+/+) homozygous splicing mutation in the ALDH3A2 gene. Other patients had the c.683G>A p.R228H (NM_000382.2) mutation in the same gene. Other manifestations included skeletal anomalies, enamel hypoplasia, bilateral T2-hyperintensities in white matter, and moderate-severe pruritus. Acitretin treatment in a maintenance dose of 0.25 mg/kg/day decreased the severity of ichthyosis in all children. It increased quality of life significantly in all of the children and their caregivers. CONCLUSION: We conclude that ichthyosis can be treated effectively with low-dose acitretin in children with Sjögren-Larsson syndrome, and this treatment is associated with a significant improvement in the quality of life.


Subject(s)
Acitretin/therapeutic use , Ichthyosis, Lamellar/drug therapy , Keratolytic Agents/therapeutic use , Sjogren-Larsson Syndrome/drug therapy , Sjogren-Larsson Syndrome/genetics , Adolescent , Aldehyde Oxidoreductases/genetics , Child , Child, Preschool , DNA Mutational Analysis , Exome , Female , Humans , Ichthyosis, Lamellar/genetics , Magnetic Resonance Imaging , Male , Musculoskeletal Abnormalities/genetics , Neuroimaging , Paraparesis, Spastic/genetics , Pedigree , Quality of Life , Sjogren-Larsson Syndrome/diagnostic imaging
4.
Muscle Nerve ; 55(4): 605-608, 2017 04.
Article in English | MEDLINE | ID: mdl-27862026

ABSTRACT

INTRODUCTION: Sjögren syndrome is thought to be a lymphocyte-driven process. Peripheral nervous system involvement occurs in about 20%-25% of patients. A sensory-predominant, large-fiber peripheral neuropathy is most common, and it is usually associated with a subacute to chronic presentation. METHODS: We report a rare case of an acute Sjögren-associated, sensory predominant, length-dependent peripheral neuropathy mimicking Guillain-Barré syndrome. The patient presented with sensory ataxia preceded by fever and polyarthralgia. She gave a history of years of dry eyes and dry mouth. RESULTS: She had a positive Shirmer test, abnormal salivary gland scan, and positive SS-A and SS-B antibodies. A sural nerve biopsy showed an unusual, dense, non-IgG4, polyclonal, plasma-cell perivascular infiltrate. The patient responded to treatment with weekly pulse intravenous methylprednisolone. CONCLUSIONS: Sjögren syndrome can present with acute-onset, sensory predominant peripheral neuropathy. The role of plasma cells in Sjögren syndrome is unexplored and deserves further study. Muscle Nerve 55: 605-608, 2017.


Subject(s)
Neutrophil Infiltration/physiology , Peripheral Nervous System Diseases/complications , Plasma Cells/pathology , Sjogren-Larsson Syndrome/blood , Sjogren-Larsson Syndrome/complications , Administration, Intravenous , Aged , Anti-Inflammatory Agents/administration & dosage , Antigens, CD/metabolism , Female , Humans , Magnetic Resonance Imaging , Methylprednisolone/administration & dosage , Neurologic Examination , Peripheral Nervous System Diseases/diagnostic imaging , Sjogren-Larsson Syndrome/diagnostic imaging , Sjogren-Larsson Syndrome/drug therapy , Sural Nerve/pathology , Sural Nerve/ultrastructure
6.
Clin Dermatol ; 30(3): 311-22, 2012.
Article in English | MEDLINE | ID: mdl-22507046

ABSTRACT

Ichthyoses, including inherited disorders of lipid metabolism, display a permeability barrier abnormality in which the severity of the clinical phenotype parallels the prominence of the barrier defect. The pathogenesis of the cutaneous phenotype represents the consequences of the mutation for epidermal function, coupled with a "best attempt" by affected epidermis to generate a competent barrier in a terrestrial environment. A compromised barrier in normal epidermis triggers a vigorous set of metabolic responses that rapidly normalizes function, but ichthyotic epidermis, which is inherently compromised, only partially succeeds in this effort. Unraveling mechanisms that account for barrier dysfunction in the ichthyoses has identified multiple, subcellular, and biochemical processes that contribute to the clinical phenotype. Current treatment of the ichthyoses remains largely symptomatic: directed toward reducing scale or corrective gene therapy. Reducing scale is often minimally effective. Gene therapy is impeded by multiple pitfalls, including difficulties in transcutaneous drug delivery, high costs, and discomfort of injections. We have begun to use information about disease pathogenesis to identify novel, pathogenesis-based therapeutic strategies for the ichthyoses. The clinical phenotype often reflects not only a deficiency of pathway end product due to reduced-function mutations in key synthetic enzymes but often also accumulation of proximal, potentially toxic metabolites. As a result, depending upon the identified pathomechanism(s) for each disorder, the accompanying ichthyosis can be treated by topical provision of pathway product (eg, cholesterol), with or without a proximal enzyme inhibitor (eg, simvastatin), to block metabolite production. Among the disorders of distal cholesterol metabolism, the cutaneous phenotype in Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limb Defects (CHILD syndrome) and X-linked ichthyosis reflect metabolite accumulation and deficiency of pathway product (ie, cholesterol). We validated this therapeutic approach in two CHILD syndrome patients who failed to improve with topical cholesterol alone, but cleared with dual treatment with cholesterol plus lovastatin. In theory, the ichthyoses in other inherited lipid metabolic disorders could be treated analogously. This pathogenesis (pathway)-driven approach possesses several inherent advantages: (1) it is mechanism-specific for each disorder; (2) it is inherently safe, because natural lipids and/or approved drugs often are utilized; and (3) it should be inexpensive, and therefore it could be used widely in the developing world.


Subject(s)
Cholesterol/administration & dosage , Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage , Ichthyosis/drug therapy , Lipid Metabolism Disorders/drug therapy , Lovastatin/administration & dosage , Administration, Topical , Algorithms , Animals , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Therapy, Combination , Epidermis/metabolism , Female , Humans , Ichthyosiform Erythroderma, Congenital/drug therapy , Ichthyosiform Erythroderma, Congenital/genetics , Ichthyosiform Erythroderma, Congenital/pathology , Ichthyosis/genetics , Ichthyosis/pathology , Lipid Metabolism Disorders/genetics , Lipid Metabolism Disorders/pathology , Male , Mice , Permeability , Phenotype , Severity of Illness Index , Sjogren-Larsson Syndrome/drug therapy , Sjogren-Larsson Syndrome/genetics , Sjogren-Larsson Syndrome/pathology
8.
Australas J Dermatol ; 52(3): 231-2, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21834825

ABSTRACT

We report the patchy normalization of lamellar ichthyotic skin in Sjögren-Larsson syndrome (SLS) following a cutaneous Trichophyton rubrum infection. The dermatophytosis was pruritic and pustular, requiring treatment which was followed by the return of the lamellar ichthyosis. We discuss the possible mechanism of this clinical observation, which in turn may direct future therapy for difficult to treat ichthyotic skin seen in conditions such as SLS.


Subject(s)
Sjogren-Larsson Syndrome/complications , Tinea/complications , Trichophyton , Adult , Female , Humans , Recurrence , Remission, Spontaneous , Sjogren-Larsson Syndrome/drug therapy , Tinea/drug therapy , Tinea/microbiology
9.
An Bras Dermatol ; 85(6): 951-3, 2010.
Article in English, Portuguese | MEDLINE | ID: mdl-21308331

ABSTRACT

We report a typical case of Sjogren-Larsson syndrome in a male patient, aged 20. The Sjogren-Larsson syndrome is a neurocutaneous, autosomal recessive and disabling condition, characterized by congenital ichthyosis, spastic paraplegia and mental retardation. It is caused by deficiency of the microsomal enzyme fatty aldehyde dehydrogenase. It has no cure, but most patients survive up to an adult age. Treatment should be multidisciplinary and dermatological therapy aims at relieving the persistent itching and ichthyosis.


Subject(s)
Sjogren-Larsson Syndrome/diagnosis , Emollients/therapeutic use , Histamine Antagonists/therapeutic use , Humans , Keratolytic Agents/therapeutic use , Male , Sjogren-Larsson Syndrome/drug therapy , Sjogren-Larsson Syndrome/pathology , Young Adult
10.
J Child Neurol ; 21(12): 1092-5, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17156709

ABSTRACT

Sjögren-Larsson syndrome is a rare hereditary metabolic disorder characterized by congenital ichthyosis, mental retardation, and spastic diplegia or tetraplegia. This genetic disease is caused by fatty acid aldehyde dehydrogenase deficiency, leading to an accumulation of long-chain alcohols. The role of enzyme in the degradation of leukotrienes paved the way to the development of a new therapeutic strategy for Sjögren-Larsson syndrome, leukotriene antagonists. We describe a 3-year-old boy with Sjögren-Larsson syndrome who had a lipid peak on proton magnetic resonance spectroscopy despite normal findings on cerebral magnetic resonance imaging. He benefited from treatment with montelukast sodium, especially with respect to the agonizing pruritus.


Subject(s)
Acetates/administration & dosage , Brain/metabolism , Leukotriene Antagonists/administration & dosage , Pruritus/drug therapy , Quinolines/administration & dosage , Sjogren-Larsson Syndrome/diagnosis , Sjogren-Larsson Syndrome/drug therapy , Aldehyde Dehydrogenase/deficiency , Brain/physiopathology , Child, Preschool , Cyclopropanes , Fatty Acids/metabolism , Humans , Ichthyosis/drug therapy , Ichthyosis/etiology , Ichthyosis/physiopathology , Leukotrienes/metabolism , Lipid Metabolism/physiology , Magnetic Resonance Imaging , Magnetic Resonance Spectroscopy , Male , Predictive Value of Tests , Pruritus/etiology , Pruritus/physiopathology , Sjogren-Larsson Syndrome/physiopathology , Sulfides , Treatment Outcome
11.
Mol Genet Metab ; 89(1-2): 111-5, 2006.
Article in English | MEDLINE | ID: mdl-16837225

ABSTRACT

Sjögren-Larsson syndrome (SLS) is caused by a deficiency of fatty aldehyde dehydrogenase (FALDH), encoded by the ALDH3A2 gene. In animal studies, the expression of the murine ortholog of FALDH, has been shown to be under the control of peroxisome proliferator-activated receptor alpha (PPARalpha). In the present study, we investigated whether the hypolipidemic drug bezafibrate, which is a pan-agonist of all PPAR-isoforms, might induce FALDH activity in human fibroblasts of control subjects and SLS patients that still have some residual FALDH activity. Our results show that FALDH activity was induced 1.4-fold after a 3-day treatment with 800 microM bezafibrate in fibroblasts of control subjects. Interestingly, in fibroblasts of two SLS patients homozygous for the p.R228C substitution, FALDH activity could be induced to 37% of control values by bezafibrate treatment. mRNA analysis in fibroblasts of these patients also revealed a mean 1.8-fold induction of FALDH mRNA after bezafibrate treatment. No induction was observed in fibroblasts of patients with mutations that cause instability of FALDH mRNA or that result in a protein without any residual activity. These data suggest that bezafibrate treatment could be effective in patients with expression of FALDH protein and some residual enzyme activity. Further research is needed to resolve whether patients could benefit from treatment with bezafibrate.


Subject(s)
Aldehyde Oxidoreductases/metabolism , Bezafibrate/therapeutic use , Hypolipidemic Agents/therapeutic use , Peroxisome Proliferator-Activated Receptors/agonists , Sjogren-Larsson Syndrome/drug therapy , Aldehyde Oxidoreductases/genetics , Cells, Cultured , Fibroblasts/drug effects , Fibroblasts/enzymology , Humans , Hypolipidemic Agents/pharmacology , Sjogren-Larsson Syndrome/enzymology , Up-Regulation
13.
Eur J Pediatr ; 160(12): 711-7, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11795678

ABSTRACT

UNLABELLED: The Sjögren-Larsson syndrome (SLS) is an inborn error of lipid metabolism, characterised clinically by congenital ichthyosis, mental retardation and spasticity. Patients also suffer from severe pruritus. The degradation of leukotriene (LT) B4 is one of the defective metabolic routes in SLS. Zileuton inhibits the synthesis of LTB4 and the cysteinyl leukotrienes. Five SLS patients were treated with zileuton for 3 months. Favourable effects were found on pruritus score (P = 0.006), general well-being, and background activity of electroencephalographic studies. Neuropsychological test results did not change significantly. There was, however, a clinically important trend towards improvement in the speed of information processing. Results of cerebral MRI and proton magnetic resonance spectroscopy did not change during therapy. Urinary concentrations of LTB4 and omega-OH-LTB4 decreased significantly (P=0.02 and P=0.003 respectively), while their concentrations in CSF were normal at baseline and remained so after therapy. CONCLUSION: Patients with Sjögren-Larsson syndrome might benefit from treatment with zileuton, especially with respect to the agonising pruritus. The findings reported here, point to a crucial role for leukotriene B4 in the pathogenesis of pruritus.


Subject(s)
Hydroxyurea/analogs & derivatives , Hydroxyurea/therapeutic use , Lipoxygenase Inhibitors/therapeutic use , Sjogren-Larsson Syndrome/drug therapy , Adolescent , Adult , Brain/pathology , Electroencephalography , Female , Humans , Hydroxyurea/metabolism , Lipoxygenase Inhibitors/metabolism , Magnetic Resonance Imaging , Magnetic Resonance Spectroscopy , Male , Neuropsychological Tests , Sjogren-Larsson Syndrome/diagnosis , Sjogren-Larsson Syndrome/metabolism
14.
Neuropediatrics ; 31(1): 1-3, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10774987

ABSTRACT

The Sjögren-Larsson syndrome (SLS) is a severe neurocutaneous disorder due to fatty aldehyde dehydrogenase (FALDH) deficiency. The recent discovery of the role of FALDH in the degradation of leukotriene B4 (LTB4) opened the way to the development of a new therapeutic strategy for SLS, i.e. 5-lipoxygenase inhibition. We treated one SLS patient with zileuton during five weeks. During the treatment period we found decreased values of LTB4 and omega-OH-LTB4. The severity of the pruritus diminished, and favorable changes in the child's behavior were observed. The height of the prominent "lipid peak" of cerebral white matter (that is characteristically found on proton magnetic resonance spectroscopy in SLS patients) decreased during treatment, and increased again when treatment was stopped. In conclusion, the beneficial effects of 5-lipoxygenase inhibition in SLS are very promising and encourage further research.


Subject(s)
Hydroxyurea/analogs & derivatives , Lipoxygenase Inhibitors , Lipoxygenase Inhibitors/administration & dosage , Sjogren-Larsson Syndrome/drug therapy , Aldehyde Oxidoreductases/deficiency , Child , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Humans , Hydroxyurea/administration & dosage , Hydroxyurea/adverse effects , Leukotriene B4/urine , Lipoxygenase Inhibitors/adverse effects , Sjogren-Larsson Syndrome/diagnosis , Sjogren-Larsson Syndrome/enzymology
15.
Br J Dermatol ; 134(6): 1023-9, 1996 Jun.
Article in English | MEDLINE | ID: mdl-8763418

ABSTRACT

Retinoid therapy represents the treatment of choice for severe inherited disorders of keratinization. This paper reviews our experience of acitretin, compares acitretin with etretinate and defines guidelines for treatment. Forty-six children have received acitretin since 1992 in our hospital: 29 children had either lamellar ichthyosis (nine), non-bullous ichthyosiform erythroderma (five), bullous ichthyosiform erythroderma (four), Sjögren-Larsson syndrome (three) or another rare condition (eight). The other 17 children who had psoriasis (16) and extensive viral warts (one), were excluded. Data on efficacy and tolerability of retinoid therapy were available for all but one patient. The cumulative follow-up was 472 months for acitretin. The mean (+/- standard deviation) optimal dosage for acitretin was 0.47 +/- 0.17 mg/kg per day, and this did not significantly differ between disorders. The overall improvement was considerable, with only three patients responding poorly. Mild to moderate mucocutaneous dryness was frequent. Minor abnormalities of liver function tests (four patients) and triglycerides (one patient) never led to changes of therapy. Irreversible side-effects did not occur. Acitretin therapy for children with inherited keratinization disorders is best started at 0.5 mg/kg per day. It represents a safe and effective treatment, provided that the minimal effective dose is maintained and that side-effects are carefully monitored. When switching from etretinate to acitretin, a 20% reduction is recommended if the etretinate dose is over 0.75 mg/kg per day or if side-effects are dose limiting. Otherwise the same dose can be used.


Subject(s)
Acitretin/therapeutic use , Etretinate/therapeutic use , Ichthyosis/drug therapy , Keratolytic Agents/therapeutic use , Acitretin/adverse effects , Child , Child, Preschool , Drug Administration Schedule , Etretinate/adverse effects , Female , Follow-Up Studies , Humans , Hyperkeratosis, Epidermolytic/drug therapy , Ichthyosis, Lamellar/drug therapy , Infant , Keratolytic Agents/adverse effects , Male , Sjogren-Larsson Syndrome/drug therapy
16.
Dermatology ; 190(4): 292-4, 1995.
Article in English | MEDLINE | ID: mdl-7655108

ABSTRACT

Two patients with Sjögren-Larsson syndrome were treated with calcipotriol in ointment and the ointment base only for 12 weeks, using a double-blind bilaterally paired comparative study. Unilateral improvement was observed in both patients in favour of the calcipotriol-treated side. The present case is the first demonstration of a substantial clinical effect of calcipotriol in the Sjögren-Larsson syndrome.


Subject(s)
Calcitriol/analogs & derivatives , Dermatologic Agents/therapeutic use , Sjogren-Larsson Syndrome/drug therapy , Adult , Calcitriol/administration & dosage , Calcitriol/therapeutic use , Dermatologic Agents/administration & dosage , Double-Blind Method , Female , Humans , Male , Ointments
SELECTION OF CITATIONS
SEARCH DETAIL
...